The FDA slapped GE Healthcare with a Class I recall--its most serious designation--for its infant resuscitation devices after the company found that malfunctions in the product could cause death.
Seno Medical Instruments raised $34.6 million of a planned $39 million Series C equity funding round. The company will use the funds for a pivotal U.S. study of its breast cancer diagnostic device, and to obtain CE mark approval for the device in Europe, it said in a statement.
GE Healthcare is readying space in Helsinki to host new startups, according to a report--a strategic way to tap into new technology as it continues to expand globally.
GE Healthcare sold Breas Medical--its manufacturer of sleep apnea and respiratory ventilators--to PBM Capital Group for an undisclosed price. PBM Capital could not reveal terms of the acquisition, company spokesman Sean Stalfort told FierceMedicalDevices.
Thermo Fisher has finally grabbed what it needed to close its $13.6 billion bid for Life Technologies – U.S. antitrust approval. But there are strings attached. For the deal to go through, the Massachusetts laboratory equipment giant must sell some divisions to GE Healthcare in an arrangement that mirrors similar agreements with European and Chinese regulators.
GE Healthcare will join with a technology R&D center in India to develop new med tech products.
Medtronic generated more Class I recalls than any of its device company rivals in 2013. The FDA assigns that status--its most serious label--when problems behind a product can cause serious injury or death.
GE and the NFL have named 16 winners in the first stage of its "Head Health Challenge"--a competition that awards each winner $300,000 to further their work in diagnosis and treatment for mild traumatic brain injury. Here are the 16 companies and research efforts that won initial grants in a partnership that proposes to put $50 million into concussion imaging technology.
GE Healthcare is tapping further into the global buildup in biologics manufacturing capacity with a $1 billion deal that gives it three businesses that Thermo Fisher Scientific has decided to unload, including its HyClone cell culture media and sera operation.
Thermo Fisher reached a major milestone in its $13.6 billion bid to buy Life Technologies, announcing that it will sell its gene modulation, cell culture and magnetic beads segments to GE Healthcare for $1.06 billion. Thermo inked the deal after the European Commission said in November it would only approve the Life Tech merger if Thermo sold off some businesses.